Pellet formulation for the treatment of the intestinal tract
AssigneeDr. Falk Pharma GmbH
InventorNorbert Otterbeck
Life of this patent
Estimating the term…
Abstract
An orally adminsterable pharmaceutical pellet formulation for the treatment of the intestinal tract is disclosed, which comprises a core and an enteric coating, the core including, as a pharmaceutical active compound, aminosalicylic acid or a pharmaceutically tolerable salt or a derivative thereof.
Claims18
A process for preparing an orally administrable pharmaceutical pellet formulation having a controlled release profile for the treatment of the intestinal tract, which pellet comprises a core including an aminosalicyclic acid as a pharmaceutically active compound or a pharmaceutically acceptable salt thereof and optionally pharmaceutically tolerable additives, wherein the active compound is present in the core in a non gel-forming polymer matrix which matrix is essentially insoluble in the intestinal tract and permeable to intestinal fluids and the active compound, the matrix-forming polymer making up at least 1% by weight of the total weight of the core, wherein the process comprises:
- mixing the active compound and the non gel-forming polymer matrix;
- scattering in a pharmaceutically tolerable additive;
- and
- extruding a moist mass of the matrix-forming polymer and the active compound.
A process for preparing an orally administrable pharmaceutical pellet formulation having a controlled release profile, which pellet comprises a core comprising 5-aminosalicylic acid (5-ASA) or a pharmaceutically acceptable salt thereof, wherein the 5-ASA is present in the core in a non gel-forming polymer matrix, wherein the matrix is essentially insoluble in the intestinal tract and permeable to intestinal fluids, the process comprises:
- mixing the 5-ASA and the non gel-forming polymer matrix;
- scattering in magnesium sterate;
- and
- extruding a moist mass.
Dependencies are inferred from the claim text.